§ 01 / 1998 selectivity1998: The selectivity claim, and what it does and does not cover
The foundational paper is Raun et al., 1998, in the European Journal of Endocrinology[1]. The investigators characterized ipamorelin across rat pituitary cells, anesthetized rats, and conscious swine. The headline finding was selectivity: ipamorelin released growth hormone with potency comparable to GHRP-6, yet at exposures greater than two hundred times the GH ED50 it did not raise adrenocorticotropic hormone, cortisol, prolactin, follicle-stimulating hormone, luteinizing hormone, or thyroid-stimulating hormone above the baseline produced by GHRH alone[1]. That cleanness against the broader pituitary axis is the original — and still most-cited — safety claim made for ipamorelin against earlier growth-hormone-releasing peptides.
The work was acute. The dosing windows were short. The species were rat and swine. The 1998 paper was never designed to answer chronic-exposure questions, and the editorial reading is that selectivity at the receptor, as described in this paper, is a narrow and useful fact — not a general license. Downstream effects of repeatedly elevating growth hormone and insulin-like growth factor 1 are governed by different biology than the immediate pituitary release the 1998 paper measured.
§ 02 / 1999 PK/PD1999: The human PK/PD work, in eight men per dose group
Gobburu et al., 1999, in Pharmaceutical Research, remains the deepest published characterization of ipamorelin pharmacology in humans[2]. The investigators gave five escalating fifteen-minute intravenous infusions — 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg — to eight healthy male volunteers per dose group, then fit a population PK/PD model to the GH response. Terminal half-life came out at approximately two hours. Clearance was 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The SC50 for half-maximal GH stimulation was 214 nmol/L, and the maximum GH production rate was 694 mIU/L/h. GH peaked at roughly 0.67 hours after dosing and declined exponentially toward baseline within hours[2].
The study reported the molecule as tolerated at all dose levels. It also has limits that the abstract does not advertise: eight subjects per dose group, men only, single dose, healthy. It tells the reader almost nothing about repeat dosing in any population, nothing about women, nothing about the elderly, and nothing about subjects with any comorbidity that might interact with the GH axis. Every estimate later quoted as the half-life of ipamorelin in humans traces back to this single study.
§ 03 / 2014 Phase 22014: The Phase 2 postoperative-ileus trial
The largest published human ipamorelin trial is Beck et al., 2014, in the International Journal of Colorectal Disease[3]. It enrolled 114 adults undergoing open or laparoscopic bowel resection and randomized them to 0.03 mg/kg IV ipamorelin twice daily versus placebo for up to seven days. The hypothesis was that a ghrelin-receptor agonist might shorten postoperative ileus — the period of impaired gastrointestinal motility that follows abdominal surgery. The primary efficacy endpoint missed: median time to first tolerated solid meal was 25.3 hours in the ipamorelin arm versus 32.6 hours in placebo, P=0.15. Treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm and 94.8 percent of the placebo arm[3].
A second Helsinn-sponsored study, NCT01280344, completed but did not lead to a regulatory submission[4]. AdisInsight and review summaries describe the discontinuation as driven by lack of efficacy rather than a safety signal[12]. The consequence for the safety record is the same either way: no Phase 3, no large or long-duration human safety database, no post-marketing surveillance, no pharmacovigilance file. Ipamorelin’s published human safety database is one short perioperative IV trial — and the high background adverse-event rate of the surgical setting makes detection of drug-attributable signals harder, not easier.
The published human safety database is one short perioperative IV trial. The high background adverse-event rate of the surgical setting makes detection of drug-attributable signals harder, not easier.
The central safety-gap framing
§ 04 / Mechanism in the ratThe mechanism the rat models do show
Beyond the pituitary, the rodent literature attaches several mechanistic observations to ipamorelin that are worth keeping in the ledger. In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (TID for 15 days) produced dose-dependent increases in longitudinal bone growth rate — from 42 to 44, 50, and 52 microns per day, respectively — without a measurable change in total IGF-1 at the timepoints sampled[15]. Chronic SC dosing in young female rats stimulated body weight gain and preserved in-vitro GH release from cultured pituitary cells of treated animals, suggesting minimal tachyphylaxis in that model and dosing pattern[16].
In ex vivo pancreatic tissue from normal and streptozotocin-diabetic rats, ipamorelin at concentrations from 10-12 to 10-6 M produced direct insulinotropic activity that was attenuated by L-type calcium channel block, alpha-2-adrenergic block, and a cholinergic-adrenergic blocker cocktail[9]. That finding is mechanistically important — it establishes that ipamorelin is not strictly pituitary-selective at the tissue level. The most recent published in-vivo work, a 2024 ferret study, showed intraperitoneal ipamorelin reduced delayed-phase cisplatin-induced body weight loss by approximately 24 percent without affecting cisplatin-induced emesis at the doses tested[13]; the seventy-two-hour window provides no information on chronic exposure.
§ 05 / The 2024 FDA reviewThe 2024 FDA reading: aggregation, immunogenicity, unnatural amino acids
The October 29, 2024 Pharmacy Compounding Advisory Committee meeting is the most recent regulatory event in ipamorelin’s record. The FDA reviewed both ipamorelin acetate and ipamorelin free base for inclusion in the 503A Bulks Regulation and recommended against inclusion of either form[5]. The briefing record focuses on three categories of concern.
First, the molecule contains three unnatural amino acids (Aib at position 1, D-2-naphthylalanine at position 3, D-phenylalanine at position 4). The FDA briefing notes that ‘generally less is known about the safety and biological properties of peptides that contain unnatural amino acids,’ including the structure and chromatographic behavior for purification of such residues and any impact on aggregation propensity[6]. Second, the agency identifies aggregation in injectable subcutaneous formulations as a CMC-level safety concern with direct immunogenicity implications[6]. Third, the briefing record references a serious adverse event including death in a development-stage IV protocol; the event is route- and protocol-specific but is part of the regulatory record[7].
Regulatory — outcome of the PCAC review
The procedural outcome was that ipamorelin acetate was removed from the interim 503B Category 2 list effective September 27, 2024, on the basis of a withdrawn nomination — not an endorsement of safety[5]. The compound sits outside any FDA-sanctioned compounding pathway as of late 2024.
§ 06 / Class signalsClass signals worth keeping in the ledger
Two class-level findings sit alongside the ipamorelin-specific record and inform any honest safety reading.
First, a 28-day rat dosing study of a different GHSR-1a agonist (GSK894281) at 0.3, 1, 10, and 60 mg/kg/day found dose-dependent myocardial degeneration and necrosis on light and electron microscopy, with elevated serum cardiac troponin I and fatty acid-binding protein 3[10]. The study was conducted specifically because cardiovascular injury had been observed in longer-term dosing across this receptor class. Ipamorelin itself has not been tested chronically in published cardiovascular safety pharmacology at comparable exposures. That absence is the point — it is the kind of finding that long-duration ipamorelin work would specifically need to rule out before any chronic human use could be considered.
Second, recombinant growth hormone — well-characterized clinically — has a documented adverse-event signature that includes fluid retention, peripheral edema, arthralgia, and carpal-tunnel-type symptoms attributed to interstitial fluid accumulation and tissue response to GH[11]. Acute ipamorelin trials were too short to capture this signature. Chronic SC dosing in non-clinical settings is, by mechanism, expected to reproduce some part of it. A systematic review of ghrelin and ghrelin-agonist studies found mostly null or inverse associations between ghrelin signaling and cancer risk and progression in animal models[17] — receptor-level reassurance that coexists with the unmeasured question of what chronic IGF-1 elevation looks like in ipamorelin-exposed humans, because no chronic ipamorelin human study has measured it.
Caution — Class cardiovascular signal
The myocardial-degeneration finding for GSK894281 was from a different GHSR-1a agonist, not ipamorelin. It is not direct evidence against ipamorelin. It is the kind of finding that chronic ipamorelin work would need to specifically rule out before chronic human use could be considered[10].
§ 07 / The vialThe supply chain is part of the safety reading
The dominant real-world ipamorelin safety risk in 2024-2026 may not be the molecule itself but the vial. Forensic pharmacovigilance analysis of gray-market injectable peptides documents systematic quality failures: residual industrial synthesis solvents (tetrahydrofuran detected in 100 percent of one seized Belgian sample set), heavy metals exceeding pharmaceutical safety thresholds (arsenic or lead in roughly 26 percent of samples), endotoxin levels exceeding safety thresholds in approximately 65 percent of online peptide samples, and label-claim purity as low as a small single-digit percentage in some products[14]. Ipamorelin participates in the same supply channels.
A molecule with a clean acute pharmacology, administered as an endotoxin-contaminated, heavy-metal-laden, mis-identified injection, is not a safe injection. That is a product-quality safety question, distinct from the receptor pharmacology, and it is the gap the FDA’s 2024 review and ongoing peptide enforcement environment[5][6] are most directly addressing.
